Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care – results from the Dresden NOAC registry

AIM: Vitamin-K antagonists (VKA) and non-vitamin-K dependent oral anticoagulants (NOAC) have been approved for anticoagulation in venous thromboembolism (VTE) and atrial fibrillation and patients previously treated with VKA are switched to NOAC therapy. Safety data for this switching are urgently ne...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Clin Pharmacol
Hlavní autoři: Beyer-Westendorf, Jan, Gelbricht, Vera, Förster, Kati, Ebertz, Franziska, Röllig, Denise, Schreier, Thomas, Tittl, Luise, Thieme, Christoph, Hänsel, Ulrike, Köhler, Christina, Werth, Sebastian, Kuhlisch, Eberhard, Stange, Thoralf, Röder, Ingolf, Weiss, Norbert
Médium: Artigo
Jazyk:Inglês
Vydáno: BlackWell Publishing Ltd 2014
Témata:
Drug Safety
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4239984/
https://ncbi.nlm.nih.gov/pubmed/24697922
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12391
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky